Biologics News
JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson
CARY, N.C., Feb. 14, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Lilly as a specialty pharmacy provider for JAYPIRCA™ (pirtobrutinib) for the treatment of adult
ORSERDU (elacestrant), FDA Approved for ER+/HER2- Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
CARY, N.C., Feb. 10, 2023—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Stemline Therapeutics Inc., as a limited distribution network specialty pharmacy provider for ORSERDU™ (elacestrant).
FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound), FDA Approved for Treatment of Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor, Available at Biologics by McKesson
CARY, N.C., Dec. 22, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected by Aadi Bioscience as a specialty pharmacy provider for FYARROTM (sirolimus protein-bound particles for injectable
REZLIDHIA (olutasidenib), FDA-Approved for Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia, Available at Biologics by McKesson
CARY, N.C., Dec. 19, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Rigel Pharmaceuticals as one of two specialty pharmacies in a limited distribution network
KRAZATI® (adagrasib), FDA Approved for Treatment of Advanced Non-Small Cell Lung Cancer Harboring the KRASG12C Mutation, Available at Biologics by McKesson
CARY, N.C., Dec. 14, 2022 — Biologics by McKesson, an independent specialty pharmacy focused on oncology and rare disease areas, has been selected by Mirati therapeutics as one of two specialty pharmacies in a limited
ELAHERE™ (mirvetuximab soravtansine-gynx), FDA Approved for Platinum-Resistant Ovarian Cancer, Available at Biologics by McKesson
CARY, N.C., December 12, 2022—Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates (ADCs), as